Literature DB >> 23787009

Long-term follow-up of spinal and bulbar muscular atrophy in Taiwan.

Ser-Chen Fu1, Hung-Chou Kuo, Chun-Che Chu, Yih-Ru Wu, Long-Sun Ro, Chin-San Liu, Chin-Chang Huang.   

Abstract

BACKGROUND/
PURPOSE: Spinal and bulbar muscular atrophy (SBMA), also known as Kennedy disease, is a rare neurodegenerative disorder presenting with insidious onset of weakness in bulbar and limb muscles. Information regarding long-term clinical and functional progression has been limited, especially for the Taiwanese population. The purpose of the study aimed to investigate early diagnosis and long-term prognosis of SBMA.
METHODS: We retrospectively analyzed 21 genetically confirmed SBMA patients who visited our hospital between 1993 and 2010, focusing on clinical symptoms, nerve conduction studies, and functional disability. We also analyzed the relationship between length of cytosine-adenine-guanine (CAG) repeats and age of disease onset.
RESULTS: Weakness developed at a mean age of 39 ± 7 years (mean ± standard deviation). The length of CAG repeats and age at onset of weakness showed inverse (but nonsignificant) correlation. The most common symptoms at initial presentation were hand tremor (86%), limb weakness (86%), and perioral fasciculation (76%). Creatine kinase (CK) was elevated in 17 out of 18 patients. Initial nerve conduction studies showed statistical difference from normal controls, especially decreased amplitudes of compound motor action potential (CMAP) and sensory nerve action potential (SNAP). Functional disability showed very slow progression, with only three patients becoming wheelchair-dependent during follow-up at a median age of 72 years.
CONCLUSION: Patients with SBMA may present with a myriad of symptoms, including limbs weakness, tremor, muscle atrophy, and perioral fasciculations. Elevated serum CK and decreased CMAP and SNAP amplitudes were supportive laboratory findings of SBMA. Disease progression was gradual, and most patients remained functionally independent many years after the onset of weakness.
Copyright © 2012. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23787009     DOI: 10.1016/j.jfma.2012.03.008

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  7 in total

Review 1.  Onset Manifestations of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease).

Authors:  Josef Finsterer; Gianni Soraru
Journal:  J Mol Neurosci       Date:  2015-10-19       Impact factor: 3.444

2.  Contractile dysfunction in muscle may underlie androgen-dependent motor dysfunction in spinal bulbar muscular atrophy.

Authors:  Kentaro Oki; Katherine Halievski; Laura Vicente; Youfen Xu; Donald Zeolla; Jessica Poort; Masahisa Katsuno; Hiroaki Adachi; Gen Sobue; Robert W Wiseman; S Marc Breedlove; Cynthia L Jordan
Journal:  J Appl Physiol (1985)       Date:  2015-02-05

3.  Perioral and tongue fasciculations in Kennedy's disease.

Authors:  José Luiz Pedroso; Thiago Cardoso Vale; Orlando G Barsottini; Acary S B Oliveira; Alberto J Espay
Journal:  Neurol Sci       Date:  2017-11-04       Impact factor: 3.307

4.  Genotype-phenotype correlation in Chinese patients with spinal and bulbar muscular atrophy.

Authors:  Wang Ni; Sheng Chen; Kai Qiao; Ning Wang; Zhi-Ying Wu
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

5.  Clinical Characteristics and Genotype-Phenotype Correlation of Korean Patients with Spinal and Bulbar Muscular Atrophy.

Authors:  Ju Sun Song; Kyung-Ah Kim; Ju-Hong Min; Chang-Seok Ki; Jong-Won Kim; Duk Hyun Sung; Byoung Joon Kim
Journal:  Yonsei Med J       Date:  2015-07       Impact factor: 2.759

6.  Only some patients with bulbar and spinal muscular atrophy may develop cardiac disease.

Authors:  Josef Finsterer; Claudia Stöllberger
Journal:  Mol Genet Metab Rep       Date:  2017-12-21

7.  Only some patients with bulbar and spinal muscular atrophy may develop cardiac disease.

Authors:  Josef Finsterer; Claudia Stöllberger
Journal:  Mol Genet Metab Rep       Date:  2017-11-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.